Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Renoprotective Efficacy of Montelukast; an Overview on Recent Advancements Publisher



Mojtahedi SY1, 2 ; Ghodsi M3 ; Pourpashang P4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pediatric Nephrology, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Pediatrics, School of Medicine Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pediatric Nephrology, Bahrami Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Nephropharmacology Published:2025


Abstract

Montelukast holds significant promise as a renoprotective agent, especially in early-stage kidney injuries. Its multifaceted mechanisms—ranging from anti-inflammatory and antioxidant actions to neutrophil inhibition—underscore its potential utility in clinical settings. Montelukast should not be used in patients with a known hypersensitivity to the drug or its components. Caution is advised for individuals with a history of psychiatric disorders or those who have phenylketonuria (PKU), as some formulations contain phenylalanine. © 2025, Society of Diabetic Nephropathy Prevention. All rights reserved.